Global Menopausal Hot Flashes Market Size, Share, Forecast Report, 2020-2027

The global Menopausal Hot Flashes market garnered revenue around USD 9.6 Billion in 2019 and projected to reach USD 16.2 Billion in 2027, with at a compound annual growth rate (CAGR) 6.1% throughout the estimate period from 2020 to 2027. Menopause is the time, which marks the end of a woman’s menstrual cycle. This can happen majorly in the age period between 40s or 50s. The most common menopausal symptoms, including vasomotor symptoms (hot flashes), insomnia, vaginal atrophy, altered cognitive function, dementia, depression, and loss of muscle mass, can affect up to 80% of women during menopause and may be severe in up to 20% of these women. The use of hormone replacement therapy (HRT) alleviates menopausal symptoms and lead to a major improvement in quality of life for women with menopausal symptoms. Alternative therapies such as herbal drugs are also effective in treating the vasomotor symptoms, urogenital atrophy symptoms, and irregular menstrual bleeding that occur in the premenopausal period. The market is dominated by North America region in 2018, which is expected to dominate by the end of 2027.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Menopausal Hot Flashes market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Menopausal Hot Flashes market growth.

The global Menopausal Hot Flashes market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

 the global market include Pfizer Inc., Novartis AG, Novo Nordisk A/S, Allergan plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., GlaxoSmithKline plc, and TherapeuticsMD, Inc.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

Global Menopausal Hot Flashes Market: Segmentation

• Menopausal Hot Flashes Market, by Treatment Type
  • Hormonal Treatment
    • Estrogen
    • Progesterone
    • Estrogen-Progesterone Combination
  • Non-hormonal Treatment
    • Antidepressants
      • Paroxetine
      • Fluoxetine
      • Venlafaxine
      • Desvenlafaxine
      • Others
    • Gabapentin
    • Pregabalin
    • Clonidine
  • Alternative treatment
    • Black Cohosh
    • Vitamin E
    • Herbal Medicines
    • Others

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Rest of EU
• Asia Pacific
  • China
  • India
  • Japan
  • Southeast Asia
  • Rest of APAC
• Central & South America
  • Brazil
  • Argentina
  • Rest of Central & South America
• Middle East and Africa
  • UAE
  • Saudi Arabia
  • Rest of MEA